This is in continuation to our dated 30th April, 2026 wherein we had informed regarding an earnings call Scheduled to be held on Friday 08th May, 2026 at 11.00 am (IST). Please find enclosed ....
INNOVACAP · price
▲ positive · ▼ negative · ● neutral filings · teal = economic event · numbered = multiple that day (click to pick). Times IST.
Innova Captab released its investor presentation ahead of an earnings call on May 8, 2026. FY26 revenue grew 31% YoY to ₹1,630 crore, EBITDA rose 26% to ₹250 crore (15.4% margin), and PAT increased 10% to ₹141 crore (8.6% margin). Q4 FY26 revenue was ₹448 crore, up 42% YoY. The company operates two segments: CDMO services (70% of revenue, growing 24% YoY) and Branded Generics (30%, growing 51% YoY). The Jammu manufacturing plant, commercialized in January 2025, is ramping up well with multiple marquee client audits completed. Key regulatory certifications (UK-MHRA, PIC/S) were received during the year. The company has 350+ CDMO customers, exports to 60+ countries, and 4,200+ products in its portfolio.
Strong double-digit revenue and profit growth reflects successful execution across both business segments. The Jammu plant ramp-up and new regulatory certifications support future expansion into regulated markets. The stock (BSE: INNOVACAP, NSE: INNOVACAP) shows solid operational momentum with improving scale.